Združene države Amerike - angleščina - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

american health packaging - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

zydus lifesciences limited - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

viona pharmaceuticals inc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate tablets are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

jurox (uk) limited - alfaxalone - solution for injection - 10 mg/ml - alfaxalone - canine, feline - neurological preparations

Irska - angleščina - HPRA (Health Products Regulatory Authority)

jurox (uk) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone - cats, dogs - neurological preparations

Irska - angleščina - HPRA (Health Products Regulatory Authority)

jurox (uk) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone - cats, dogs, rabbits - neurological preparations

Irska - angleščina - HPRA (Health Products Regulatory Authority)

jurox (uk) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone

Združene države Amerike - angleščina - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - indications and usage sucralfate tablets, usp are indicated in: short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - alfaxalone - solution for injection - alfaxalone